Samsung BioLogics has completed its full acquisition of Samsung Bioepis Co., Ltd., purchasing Biogen, Inc.’s 50% -1 equity stake in the former joint venture for $2.3bn. An initial payment of $1.0bn has now been made, with the remaining $1.25bn to be paid in instalments over the next two years.
Biogen Exits Joint Venture As Samsung Biologics Buys Out Bioepis
Sale Price Of $2.3bn To Be Paid Over Next Two Years
Biogen’s stake in Samsung Bioepis has been fully acquired by former partner Samsung Biologics, following an announcement of the deal in January.
More from Deals
• By
Organon has swelled its immunology biosimilar portfolio after acquiring the US commercial rights to Bio-Thera’s tocilizumab biosimilar from Biogen, which last year decided to retain its interests in biosimilars following a lengthy strategic review.
• By
India’s Dr Reddy’s and China’s Bio-Thera have struck a deal covering ustekinumab and golimumab biosimilars in multiple markets in south-east Asia.
• By
Cipla has bolstered its ophthalmology portfolio and increased its global offering after chalking up an agreement to add Formosa Pharmaceuticals’ USFDA-approved clobetasol propionate 0.05% ophthalmic suspension.
• By
Along with financial backing from the Canadian government, a fresh, decade-long partnership with Sandoz Canada will allow Delpharm to carry out modernization plans for its manufacturing facility in Boucherville, securing the local supply chain for sterile injectable medicines.